neoplasm
• tamoxifen treated mice develop intestinal adenomas after the sporadic loss of the remaining Apc allele
|
• tamoxifen treated mice develop colon adenomas after the sporadic loss of the remaining Apc allele
|
homeostasis/metabolism
• tamoxifen-treated mice show activation of autophagy in tumoral cells
|
mortality/aging
• tamoxifen treated mice show signs of illness and have to be euthanized at 135 days due to large tumor burden
|
growth/size/body
digestive/alimentary system
• tumors of tamoxifen treated mice in the distal colon and rectum are associated with frequent rectal prolapse
|
• tamoxifen treated mice develop intestinal adenomas after the sporadic loss of the remaining Apc allele
|
• tamoxifen treated mice develop colon adenomas after the sporadic loss of the remaining Apc allele
|
• in tamoxifen treated mice
• prolonged antibiotic administration of tamoxifen treated mice does not affect severity of polyposis
• metaformin treatment impairs the growth of polyps in tamoxifen-treated mice but does not affect adenoma cell proliferation
|
• tamoxifen treated mice show a difference in the overall composition of both fecal and ileal microbiota compared to double conditional mice heterozygous for Apc and homozygous for Atg7, with mice showing high levels of Gram- bacteria mostly from Helicobacter in the feces
• ileal mucosa of tamoxifen treated mice has a lower bacterial diversity than in double conditional mice heterozygous for Apc and homozygous for Atg7
• the ratio of Gram- to Gram+ bacteria is lower in tamoxifen treated mice than in double conditional mice heterozygous for Apc and homozygous for Atg7
|
cellular
• tamoxifen-treated mice show activation of autophagy in tumoral cells
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
colorectal cancer | DOID:9256 |
OMIM:114500 |
J:227287 |